|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

* Institute of Molecular Biology and Biochemistry, Center of Molecular Medicine, Medical University Graz, Harrachgasse 21/III, Graz A-8010, Austria
Institute of Molecular Biology, Biochemistry and Microbiology, University of Graz, Heinrichstrasse 31a, Graz A-8010, Austria
Published, JLR Papers in Press, April 16, 2005. DOI 10.1194/jlr.M500054-JLR200
1 To whom correspondence should be addressed. e-mail: sasa.frank{at}meduni-graz.at
| ABSTRACT |
|---|
|
|
|---|
The lack of phospholipase A2 activity of EL and its ability to liberate [14C]FA from [14C]lysophosphatidylcholine (lyso-PC) led us to conclude that EL-mediated deacylation of phosphatidylcholine (PC) is initiated at the sn-1 position, followed by the release of the remaining FA from the lyso-PC intermediate. Thin-layer chromatography analysis of cellular lipids obtained from EL-overexpressing cells revealed a pronounced accumulation of [14C]phospholipid and [14C]triglyceride upon incubation with 1-palmitoyl-2-[1-14C]linoleoyl-PC-labeled HDL3, indicating the ability of EL to supply cells with unsaturated FAs.
Abbreviations: DMEM, Dulbecco's modified Eagle's medium; EL, endothelial lipase; EL-Ad, adenovirus encoding human endothelial lipase; FA, fatty acid; FCS, fetal calf serum; FFA, free fatty acid; GC, gas chromatography; HDL-PC, HDL phosphatidylcholine; LacZ-Ad, adenovirus encoding ß-galactosidase; lyso-PC, lysophosphatidylcholine; MOI, multiplicity of infection; PAPC, 1-palmitoyl-2-arachidonylphosphatidylcholine; PL, phospholipid; plasmalogen-PC, 1-O-1'-hexadecenyl-2-arachidonoylphosphatidylcholine; PLPC, 1-palmitoyl-2-linoleoylphosphatidylcholine; POPC, 1-palmitoyl-2-oleoylphosphatidylcholine; TG, triglyceride; TLC, thin-layer chromatography
Supplementary key words phospholipases lysophospholipases phospholipids polyunsaturated fatty acid reconstituted high density lipoprotein
| INTRODUCTION |
|---|
|
|
|---|
Initial studies on EL activity, using phosphatidylcholine (PC) labeled in the sn-1 position, established phospholipase A1 (PLA1) activity of the enzyme (2). Accordingly, sn-1 fatty acids (FAs) from HDL phosphatidylcholine (HDL-PC), the most abundant HDL-PL (10), are released by EL. The ability of EL to release [14C]arachidonic acid from the 1-stearoyl-2-[1-14C]arachidonyl PC-labeled HDL (11) suggested sn-2 phospholipase activity of EL. Furthermore, we found a decreased amount of the fatty acid synthase (FAS) mRNA and a decreased rate of fatty acid synthesis in EL-overexpressing cells (12). This was most likely a consequence of the suppressing effect of polyunsaturated fatty acids on the expression of cellular lipogenic genes, including FAS (13).
In this report, we provide evidence for the ability of EL to liberate saturated as well as unsaturated FAs from reconstituted discoidal HDL (rHDL) and HDL3-PC. We found that the mechanism of unsaturated FA release does not involve sn-2 phospholipase activity. Instead, the release of unsaturated FA requires two enzyme activities of EL, sn-1 phospholipase activity and lysophospholipase activity. Furthermore, we demonstrated the ability of EL to supply cells with unsaturated sn-2 FAs.
| EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
Isolation of human HDL
HDL (subclass 3, d = 1.1251.21 g/ml) was prepared by sequential ultracentrifugation of plasma obtained from normolipidemic blood donors as described previously (5, 12). After ultracentrifugation, HDL was dialyzed against PBS (pH 7.4), and the protein concentration was determined by the Lowry method (14).
Preparation of rHDL
Discoidal rHDL containing either 1-palmitoyl-2-oleoylphosphatidylcholine (POPC), 1-palmitoyl-2-linoleoylphosphatidylcholine (PLPC), 1-palmitoyl-2-arachidonylphosphatidylcholine (PAPC), plasmalogen-PC [1-O-1' (Z)-hexadecenyl-2-arachidonylphosphatidylcholine] (Avanti%20Polar%20Lipids">Avanti Polar Lipids), free cholesterol (FC) (Sigma-Aldrich, St. Louis, MO) and apoA-I (kindly provided by Dr. G. M. Kostner) were prepared as described previously (15). Briefly, 3.29 µmol of the corresponding phospholipid was mixed with 13.9 nmol of FC, followed by the removal of chloroform by evaporation under a stream of argon. To the resulting film, 200 µl of Na-cholate (10% Na-cholate in 0.2 M potassium phosphate buffer, pH 7.4) was added dropwise with vortexing to give a clear solution, followed by the dropwise addition with vortexing of 559.2 µl of apoA-I (3.29 nmol). The resulting solution was extensively dialyzed against degassed PBS under argon at 4°C. The rHDLs were freshly prepared for each experiment, stored under argon at 4°C, and used within 3 days.
Analysis of FFAs released from POPC-, PLPC-, PAPC-rHDL, and HDL3 by gas chromatography
To analyze FFAs liberated from rHDL-PL by EL, 350 µg rHDL (protein) was incubated with EL-conditioned medium (850 µl) and FFA-free BSA (Sigma) (50 µl) prepared as a stock solution (100 mg/ml) in Panserin 401 medium in a water bath at 37°C for 20 h. For the analyses of FFAs liberated from HDL3, 500 µg HDL3 (protein) was incubated with 446 µl EL-conditioned medium in the presence of FFA-free BSA (1%) for 20 h at 37°C. In the control incubations, EL-conditioned medium was replaced with LacZ-conditioned medium. Subsequently, incubation mixtures were split and one aliquot was extracted twice with hexane-isopropanol (3:2; v/v) containing glacial acetic acid (0.01%; v/v), evaporated under N2, redisolved in chloroform, and loaded onto thin-layer chromatography (TLC) plates. The TLC separation of lipids was performed under argon using hexane-diethylether-glacial acetic acid (70:29:1; v/v/v) as the mobile phase. The lane loaded with oleic acid as a marker for the FFA migration was cut off the TLC plate, exposed to I2 vapor, and used to determine the zones corresponding to FFA. The FFAs were scraped from the plates, followed by transesterification and gas chromatographic analysis as described (16). Briefly, 10 µg pentadecanoic acid as an internal standard was added to the scraped material, and transesterification was performed in the presence of 1 ml toluene and 1 ml boron trifluoride-methanol (20%) at 110°C for 60 min. Excess boron trifluoride was destroyed by the addition of 2 ml water, and the fatty acid methyl esters were extracted into 200 µl of hexane (final volume of the organic phase containing hexane and toluene was
1.7 ml). Two microliters were analyzed by gas chromatography (GC). Separation of fatty acid methyl esters was performed on a CP-FFAP CB column (25 m, 0.32 mm id) using an Hewlett Packard (HP) 5890 gas chromatograph (CHROMPACK, Palo Alto, CA) equipped with a flame-ionization detector and a split/splitless injector. Helium was used as carrier gas; the split ratio was
10:1. The initial temperature, at 150°C, was programmed to 215°C at 2.5°C/min with a hold at 215°C for 10 min, then programmed to 230°C at 10°C/min with a hold at this temperature for 12.5 min. The detector temperature was 300°C, and the injector temperature was 300°C. Concentrations of fatty acids were calculated by peak area comparison with an internal standard.
Analysis of PC and lyso-PC in EL and LacZ incubation mixtures using POPC-, PLPC-, PAPC-rHDL, and HDL3 as substrates by tandem MS
For MS analysis, aliquots of the EL and LacZ incubation mixtures used for the analysis of FFA (see above) were extracted according to the method of Bligh and Dyer (17). Dried samples were redissolved with chloroform-methanol (2:1; v/v) and mixed with an equal volume of the internal standard solution [8.8 mg 1,2-distearoyl-D70-3-sn-glycerophosphatidylcholine in 10 ml chloroform-methanol (2:1; v/v)]. The mixture was diluted 1:100 with chloroform-methanol (2:1; v/v), and 20 µl of the diluted sample was mixed with 20 µl ammonium hydrogen carbonate solution and 160 µl chloroform-methanol (2:1; v/v). The mixture was used for MS analysis in a positive mode using the TSQ7000 triple quadrupole mass spectrometer (Finnigan-MAT; San Jose, CA) equipped with off-line nano-electrospray ion source (Protana; Odense, Denmark). PCs were detected by precursor ion scanning of m/z 184 in the positive ion mode with the following settings: spray voltage, 800 V; scan time, 4001,200 m/z 4 s; collision energy, 35 eV. The scan was performed for 4 min, and
60 tandem MS scans were averaged. The internal standard peak at m/z 860 was used to calculate a correction factor to compare the peak intensities of different samples (18).
Assay of sn-2-phospholipase activity
To assess whether EL exhibits PLA2 activity, 150 µg rHDL containing plasmalogen-PC as the only PL was incubated with EL- and LacZ-conditioned medium in the presence of 1% FFA-free BSA at 37°C. As a positive control, rHDL containing plasmalogen-PC (150 µg) was incubated with 0.46 mU PLA2 from porcine pancreas (Sigma) in PBS in the presence of 10 mM CaCl2 and 1% FFA-free BSA. Aliquots (10 µl) were removed from the incubation mixtures at the indicated time points, and the release of FFA from plasmalogen-PC was determined using a commercial kit (NEFA-C; Wako Chemicals). After 20 h incubation, mixtures were extracted according to the method of Bligh and Dyer (17). The chloroform phase was evaporated under N2, and lipids were redissolved with 50 µl of a chloroform-methanol (2:1; v/v) solution and applied on a TLC plate. Lipids were separated using chloroform-methanol-acetic acid-water (25:15:4:2; v/v/v/v) as the mobile phase and visualized by spreading 10% H2SO4 onto the plate, followed by heating at 120°C for 15 min.
Assay of lysophospholipase activity
The lysophosphatidylcholine (lyso-PC) substrate was prepared by mixing 1 µCi (18.18 nmol) of 1-[1-14C]palmitoyl-2-lyso-PC (NEN; Boston, MA) with 901 µg (1.82 µmol) of unlabeled 1-palmitoyl-2-lyso-PC (Avanti%20Polar%20Lipids">Avanti Polar Lipids). The mixture was dried under a stream of N2 and redissolved in 30 µl ethanol. Subsequently, lipids were solubilized in 970 µl DMEM by vortexing. For the time course experiment, aliquots (20 µl) of the lyso-PC mixture were mixed with 280 µl of EL- or LacZ-conditioned medium and incubated in the presence of 1% FFA-free BSA at 37°C for various periods of time, as indicated in the legend to Fig. 5A. Incubation mixtures were extracted twice with hexane-isopropanol (3:2; v/v) containing 1 N HCl, evaporated under N2, redisolved in chloroform, and applied onto TLC plates. The TLC separation of lipids was performed using hexane-diethylether-glacial acetic acid (70:29:1; v/v/v) as the mobile phase. The TLC plate was exposed to I2 vapor, and zones corresponding to FFA were cut out of the TLC plate and mixed with a scintillation cocktail, and radioactivity was determined on a ß-counter (Beckman). For the dose-dependent study, increasing amounts of the lyso-PC mixture (560 µl) were incubated in a total volume of 280 µl of EL- or LacZ-conditioned medium at 37°C for 30 min. Samples were further processed as described for the time course experiment.
|
Time course of in vitro EL-mediated hydrolysis of 1-palmitoyl-2-[1-14C]linoleoyl-PC-labeled HDL3
1-Palmitoyl-2-[1-14C]linoleoyl-PC-labeled HDL3 (40 µg) was mixed with 425 µl of EL and LacZ incubation medium in the presence of 1% FFA-free BSA and incubated in a water bath at 37°C. At the indicated time points, incubation mixtures were extracted according to the method of Bligh and Dyer (17). Lipids were separated by TLC using chloroform-methanol-water (65:35:6; v/v/v) as the mobile phase, followed by exposure to a 14C screen (Kodak) and visualization on the Storm imager (Amersham Biosciences). The signals corresponding to PC, lyso-PC, and FFA were cut out of the TLC plate, mixed with a scintillation cocktail, and measured on a ß-counter.
TLC analysis of 14C lipids in cell media and cells expressing EL, EL-Mut, and LacZ
HepG2 cells were plated onto 24-well trays and infected after 36 h with EL-, EL-Mut-, and LacZ-Ad at an MOI of 60. EL-Mut-Ad encodes catalytically inactive EL (5, 12). At 24 h postinfection, cells were washed twice with PBS and incubated with 300 µl DMEM containing the indicated concentrations of 1-palmitoyl-2-[1-14C]linoleoyl-PC-labeled HDL3 and 2% FFA-free BSA under standard culture conditions. After 5 h, medium was collected and cells were incubated with DMEM containing 100 U/ml heparin to remove labeled HDL3 bound to the cell surface. Subsequently, cells were extensively washed with PBS. The lipids were extracted twice from the media and cells using hexane-isopropanol (3:2, v/v), dried in the speed vac, and redissolved in chloroform before application onto the TLC plates. Hexane-diethylether-glacial acetic acid (70:29:1; v/v/v) was used as the mobile phase. Spots corresponding to PL, TG, and FFA were visualized upon exposure of the TLC plates to a 14C screen (Kodak) on the Storm imager, cut out of the TLC plates, and measured by scintillation counting.
Statistics
Data are expressed as mean ± SD. Significance of differences was examined using Student's t-test.
| RESULTS |
|---|
|
|
|---|
|
2-fold lower compared with 16:0. The concentrations of 20:4 and 16:1 were 10- and 24-fold lower in the EL incubation mixture compared with 16:0 (Fig. 2). MS analyses of the incubation mixtures revealed a considerable EL-mediated increase in 18:2-lyso-PC, followed by 16:0-, 20:4-, 18:1-, and 18:0-lyso-PC, respectively (Fig. 2C). These results clearly demonstrated the ability of EL to liberate both saturated and unsaturated FAs from its natural substrate, HDL-PC.
|
|
|
|
|
EL supplies cells with unsaturated sn-2 FAs
Next, we examined whether EL can supply cells with unsaturated, sn-2 FAs, released from HDL-PC. For this, HepG2 cells were infected with EL-Ad, EL-Mut-Ad [an adenovirus encoding catalytically inactive EL (5, 12)], and LacZ-Ad and incubated with increasing concentrations of P-LPC-labeled HDL3. TLC analyses of cell media after a 5 h incubation period revealed a pronounced dose-dependent accumulation of [14C]18:2 FFA in the media of EL-Ad-infected cells (Fig. 6A). In the media of EL-Mut-Ad- and LacZ-Ad-infected cells, the amount of [14C]18:2 FFA was 6-fold lower than in EL media. TLC analysis of cellular lipid extracts showed that EL-Ad-infected cells accumulated profoundly higher amounts of [14C]TGs (Fig. 6B) and [14C]PL (Fig. 6C) compared with EL-Mut-Ad- and LacZ-Ad-infected cells. These results clearly demonstrate that the interplay of both phospholipase and lysophospholipase activity in EL is a prerequisite for the supply of cells with unsaturated FAs from HDL-PC, which are, in turn, incorporated into endogenous lipids.
|
| DISCUSSION |
|---|
|
|
|---|
The results of the present study revealed that the rates of the EL-mediated release of the sn-2 FAs 18:1 and 18:2 were comparable but significantly exceeded that of the sn-2 FA 20:4. This effect was even more pronounced when HDL3 was used as a substrate for EL. HDL3 contained a 2.8-fold lower amount of the PC subspecies 36:4 (16:0/20:4) and 38:4 (18:0/20:4), both serving as sources of FA 20:4, compared with the PC subspecies 34:2 (16:0/18:2) and 36:2 (18:0/18:2) containing FA 18:2. Therefore, the 4.5-fold lower amount of FA 20:4 released by EL compared with FA 18:2 could not be explained by a low relative abundance of the PC subspecies supplying FA 20:4. Accordingly, it is tempting to speculate that the degree of unsaturation and the acyl chain length affect the cleavage efficiency of FA 20:4 from PC by EL.
We clearly demonstrated in the present study that EL lacks sn-2 phospholipase activity. However, like hepatic lipase (20, 21), EL has the ability to hydrolyze lyso-PC. Accordingly, the lower rate at which FA 20:4 is released from HDL-PC by EL, compared with the FAs 18:1 and 18:2, might be accounted for by a less-efficient EL-mediated hydrolyzation of 20:4-lyso-PC, compared with 18:1- and 18:2-lyso-PC. However, further experiments are required to clarify the impact of the acyl chain length and unsaturation on the rate of lyso-PC hydrolysis by EL.
In contrast to FAs 18:2 and 20:4, which reside on the sn-2 position of PC, 18:1 is distributed between both positions. For example, in PC 36:3, this FA resides on the sn-1 position; in PC 34:1, on the sn-2 position; and in PC 36:2 (18:0/18:2 or 18:1/18:1), on both positions. Accordingly, 18:1 released from HDL3-PC by EL originates from both sn positions. Our analysis using GC revealed a strikingly high relative abundance of 16:0- and 18:0-lyso-PC in the EL-HDL3 incubations, even at conditions of low relative abundance of the PC subspecies 32:0 and 36:0 in HDL3. A possible explanation might be an efficient generation of these lyso-PC subspecies but their very inefficient cleavage by EL.
Experiments in which plasmalogen-PC, containing a nonhydrolyzable sn-1 position, was used as a substrate for EL have shown that EL completely lacks sn-2 phospholipase activity. From these results, we conclude that the initial EL-mediated deacylation occurs at the sn-1 position, resulting in a lyso-PC intermediate, which is, in turn, deacylated by the lysophospholipase activity of EL. Two lines of evidence support this assumption. First, a [14C]linoleoyl-lyso-PC intermediate is formed upon the action of EL on 1-palmitoyl-2-[1-14C]linoleoyl-PC (P-LPC) prior to the release of [14C]linoleic acid. Second, EL has the ability to hydrolyze 1-[1-14C]acyl-2-lyso-PC. It is well known that in aqueous medium at neutral pH, acyl chains rapidly migrate from the sn-2 to the deacylated sn-1 position to give a more stable intermediate (19). Therefore, it is very reasonable to assume such FA migration also under our experimental conditions. After an initial EL-mediated deacylation of HDL-PC, the remaining sn-2 acyl chain migrates to the sn-1 position, where it is, in turn, cleaved by the sn-1 phospholipase activity of EL. In light of these results, it is tempting to speculate that a less-efficient release of FA 20:4, compared with 18:1 and 18:2, from rHDL- or HDL3-PC by EL might be independent of EL substrate preference and, in fact, could be due to a less-efficient migration of 20:4 to the sn-1 position for cleavage by EL-lysophospholipase activity.
Commercially available lyso-PC was a 9:1 mixture of sn-1- and sn-2-acyl-lyso isomers (22, 23). Therefore, although it is unlikely, we cannot rule out the possible contribution of the sn-2 lysophospholipase activity of EL. To address the regiospecificity of EL, we aimed at monitoring the rate of hydrolyses of sn-1- and sn-2 acyl-lyso-PC isomers by [31P]NMR. This method requires high enzymatic activities in the studied enzyme, to promote rapid conversion of high amounts of substrate into a corresponding product (19). However, the relatively low abundance of EL in conditioned media, and the low yield of enzymatically active EL upon further purification, impeded [31P]NMR analysis. Because acyl migration is inhibited at pH 5.5 (19), the ability of EL to release [14C]FA from a 1-acyl-2-[1-14C]acyl-PC at pH 5.5 would provide information on the regiospecificity of EL lysophospholipase activity. Unfortunately, at pH 5.5, both phospholipase and lysophospholipase activities of EL were nearly absent (not shown), precluding the possibility of addressing the regiospecificity of EL lysophospholipase activity by this approach.
Our previous study (12) indicated that FAs liberated by EL from HDL-PL are incorporated into endogenous lipids in EL-expressing cells. Because 1,2-di[1-14C]palmitoyl-PC was used as a tracer in that study, we could not discriminate between [14C]FAs released only from the sn-1 or sn-2 positions of HDL-PC. In the present study, using 1-palmitoyl-2-[1-14C]linoleoyl-PC-labeled HDL3, we demonstrated the ability of EL to supply cells with sn-2 [14C]FAs, which, in turn, are incorporated into cellular TG and PL. Markedly higher accumulation of [14C]TG and [14C]PL in EL-compared with EL-Mut-expressing cells excluded the possibility that the accumulation of the 14C label in the cells is due to [14C]HDL particle uptake and selective uptake of [14C]HDL-PC, processes that might be mediated by the bridging function of EL (12, 24). A recent study demonstrated the ability of EL that is upregulated in the lipoprotein lipase (LPL)-deficient adipose tissue (AT) to supply that tissue with HDL-PC-derived FAs (25). Although EL only partially normalized FA import in adipocytes when LPL was absent, these in vivo results substantiate the role of EL in supplying cells and tissues with FAs derived from HDL-PC. Interestingly, LPL-deficient AT exhibited a highly significant reduction of FA 18:2 and a significant increase of FAs 16:1 and 18:1, respectively, in both TG and PL moiety. This finding is not in line with our results, demonstrating that amounts of FAs 18:1 and 18:2 released by EL from HDL-PC were similar and markedly higher compared with FA 16:1 (Fig. 2). This discrepancy might be due, at least in part, to the difference between human HDL3 and mouse lipoproteins with regard to FA composition in their PC moiety.
Unsaturated FAs, notably 18:1 and 18:2, which can be supplied to cells by EL, have been shown to interfere with tumor necrosis factor-
(TNF-
)-induced expression of vascular adhesion molecule 1 (26, 27). Considering the fact that EL is upregulated by TNF-
(28), it is tempting to speculate that under inflammatory conditions, expression of adhesion molecules on vascular endothelium is, at least in part, affected by EL. Furthermore, considering the fact that EL has the ability to supply endothelial cells with HDL-derived arachidonic acid, which exerts a stimulatory effect on prostacyclin synthesis (29), EL might have an impact on vasorelaxation.
Taken together, our results indicate that EL has the ability to liberate both saturated and unsaturated FAs from HDL-PC because of its sn-1 phospholipase and lysophospholipase activity. Saturated and unsaturated FAs liberated from HDL-PC by EL are supplied to EL-expressing cells and are rapidly incorporated into endogenous lipids.
| ACKNOWLEDGMENTS |
|---|
Manuscript received February 10, 2005 and in revised form March 30, 2005.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Gauster, U. Hiden, A. Blaschitz, S. Frank, U. Lang, G. Alvino, I. Cetin, G. Desoye, and C. Wadsack Dysregulation of Placental Endothelial Lipase and Lipoprotein Lipase in Intrauterine Growth-Restricted Pregnancies J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2256 - 2263. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Qiu, A. C. Ho, W. Yu, and J. S. Hill Suppression of endothelial or lipoprotein lipase in THP-1 macrophages attenuates proinflammatory cytokine secretion J. Lipid Res., February 1, 2007; 48(2): 385 - 394. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Magnusson-Olsson, B. Hamark, A. Ericsson, M. Wennergren, T. Jansson, and T. L. Powell Gestational and hormonal regulation of human placental lipoprotein lipase J. Lipid Res., November 1, 2006; 47(11): 2551 - 2561. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Jin, I. V. Fuki, N. G. Seidah, S. Benjannet, J. M. Glick, and D. J. Rader Proprotein Covertases Are Responsible for Proteolysis and Inactivation of Endothelial Lipase J. Biol. Chem., November 4, 2005; 280(44): 36551 - 36559. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||